Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems

Table 1 Distribution of c-Jun, N-ras, Caspase9 and p73 expression in different subtypes of thymic epithelial tumors (TETs) n (%)

	Type-A	Type-AB	Type-B1	Type-B2	Type-B3	Tca^a	MT^b	Total	NT^c	P ^d	P ^e	P ^f
	N = 2	N = 19	N = 4	N = 14	N = 11	N = 8	N = 2	N = 60	N = 11
C-Jun	0 (0.0)	4 (21.0)	0 (0.0)	6 (42.9)	5 (45.5)	7 (87.5)	0 (0.0)	22 (36.7)	0 (0)	0.011	0.014	0.002
N-ras	1 (50.0)	3 (15.8)	0 (0.0)	1 (7.1)	5 (45.4)	2 (25.0)	0 (0.0)	12 (20.0)	3 (27.3)	0.187	0.888	0.364
Caspase9	2 (100.0)	5 (26.3)	0 (0.0)	10 (71.4)	7 (63.6)	4 (50.0)	2(100.0)	30 (50.0)	7 (63.6)	0.016	0.780	0.019
p73	1 (50.0)	5 (35.7)	0 (0.0)	9 (64.3)	8 (81.8)	4 (50.0)	1 (50.0)	28 (46.6)	1 (9.1)	0.044	0.046	0.004

Tca^a: thymic carcinoma.
MT^b: metaplastic thymoma.
NT^c: normal thymic tissue.
P^d: Two-sided Fisher’s exact test for distributions between different histologic subtypes of thymoma.
P^e: Two-sided Fisher’s exact test for distributions between cases and controls.
P^f: Two-sided Pearson’s chi square test for distributions between lower-grade TETs (type-A, AB, B1,MT) and higher-grade TETs (type-B2, B3, Tca).

ISSN: 1746-1596